{"id":"ef66fee2-c520-5b7e-bd41-78571bcce612","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-needs-cr3-c3-and-granulocytes","predicate":"amplifies","statement":"In comparison with antitumour monoclonal antibody or beta-glucan alone, combined treatment produced significantly greater tumour regression in all five models, tumour-free survival only occurred in models that incorporated stable expression of the target antigen, beta-glucan enhancement of the monoclonal antibody tumoricidal response did not occur in mice deficient in either leukocyte CR3 or serum C3 confirming the requirement for CR3 on leukocytes and iC3b on tumours, and granulocytes appeared to be primarily responsible for tumoricidal activity because beta-glucan therapeutic responses did not occur in granulocyte-depleted mice.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"f07deedc-0f27-58e3-9577-b369c33d3369","mechanism_event_label":"Take away the complement protein, the receptor, or the granulocytes, and the effect disappears entirely.","subject":{"id":"1e73e18e-eca0-56b0-b3de-a850ea95344f","slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"},"object":{"id":"d3889da6-26a5-53db-8524-995e87aa75ba","slug":"antitumour-monoclonal-antibody","display_name":"Complement-activating antitumour monoclonal antibodies","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"f07deedc-0f27-58e3-9577-b369c33d3369","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-needs-cr3-c3-and-granulocytes-event","event_type":"biochemical_relationship","label":"Take away the complement protein, the receptor, or the granulocytes, and the effect disappears entirely.","description":"In comparison with antitumour monoclonal antibody or beta-glucan alone, combined treatment produced significantly greater tumour regression in all five models, tumour-free survival only occurred in models that incorporated stable expression of the target antigen, beta-glucan enhancement of the monoclonal antibody tumoricidal response did not occur in mice deficient in either leukocyte CR3 or serum C3 confirming the requirement for CR3 on leukocytes and iC3b on tumours, and granulocytes appeared to be primarily responsible for tumoricidal activity because beta-glucan therapeutic responses did not occur in granulocyte-depleted mice.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"309b5460-2ec8-5c78-ada2-8637d6991433","slug":"cr3-complex","display_name":"Complement receptor 3 / CD11b-CD18","entity_type_key":"protein_complex"},"role":"required_receptor","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"aaf8cb37-596c-5a35-aae0-614623b264fe","slug":"complement-c3","display_name":"Complement component C3","entity_type_key":"protein"},"role":"required_protein","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"a1abb369-49cb-512c-9807-1591b9307567","slug":"granulocyte","display_name":"Granulocyte","entity_type_key":"cell_type"},"role":"required_effector","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"04e0de91-27e8-50a3-9ad9-ff234a10cfc0","slug":"ic3b","display_name":"The complement fragment iC3b","entity_type_key":"protein_state"},"role":"required_target_marker","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"7e39f8b2-8b39-5f3b-bb37-ca39a7f72221","slug":"tumour-cell-killing","display_name":"Killing of antibody-opsonised tumour cells by leukocytes","entity_type_key":"cellular_process"},"role":"measured_process","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"1e73e18e-eca0-56b0-b3de-a850ea95344f","slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""},{"entity":{"id":"d3889da6-26a5-53db-8524-995e87aa75ba","slug":"antitumour-monoclonal-antibody","display_name":"Complement-activating antitumour monoclonal antibodies","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":6,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/14695221.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"810d6af738d83f5bd304be109db27808437a1f7fb7398253366d88d0b258ccc5\", \"start_char\": 0, \"end_char\": 1827, \"text_sha256\": \"810d6af738d83f5bd304be109db27808437a1f7fb7398253366d88d0b258ccc5\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Five mouse tumour models with antitumour monoclonal antibody, in CR3-deficient, C3-deficient and granulocyte-depleted animals","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Intravenous beta-glucan combined with antitumour monoclonal antibodies in BALB/c and C57Bl/6 mice","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Five models with genetic and depletion controls, which is what makes the requirement claim strong. Tumour-free survival occurred only where the target antigen was stably expressed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Mouse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Take away the complement protein, the receptor, or the granulocytes, and the effect disappears entirely.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p14695221] Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. (2003). https://pubmed.ncbi.nlm.nih.gov/14695221/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Mammary, subcutaneous and hepatic tumours","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"dd50d93e-836e-5be7-b749-4dd04f326251","evidence_kind":"source_excerpt","locator":"Lines 229-240","start_line":229,"end_line":240,"excerpt":"### bg-needs-cr3-c3-and-granulocytes\nIn comparison with antitumour monoclonal antibody or beta-glucan alone, combined treatment produced significantly greater tumour regression in all five models, tumour-free survival only occurred in models that incorporated stable expression of the target antigen, beta-glucan enhancement of the monoclonal antibody tumoricidal response did not occur in mice deficient in either leukocyte CR3 or serum C3 confirming the requirement for CR3 on leukocytes and iC3b on tumours, and granulocytes appeared to be primarily responsible for tumoricidal activity because beta-glucan therapeutic responses did not occur in granulocyte-depleted mice.\nCondition category: machinery_impairment\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: Take away the complement protein, the receptor, or the granulocytes, and the effect disappears entirely.\norganism: Mouse\ntissue_or_cell_type: Mammary, subcutaneous and hepatic tumours\nexperimental_model: Five mouse tumour models with antitumour monoclonal antibody, in CR3-deficient, C3-deficient and granulocyte-depleted animals\nlimitations: Five models with genetic and depletion controls, which is what makes the requirement claim strong. Tumour-free survival occurred only where the target antigen was stably expressed.\nexposure: Intravenous beta-glucan combined with antitumour monoclonal antibodies in BALB/c and C57Bl/6 mice\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/14695221.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"810d6af738d83f5bd304be109db27808437a1f7fb7398253366d88d0b258ccc5\", \"start_char\": 0, \"end_char\": 1827, \"text_sha256\": \"810d6af738d83f5bd304be109db27808437a1f7fb7398253366d88d0b258ccc5\"}\n[bg-p14695221] Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. (2003). https://pubmed.ncbi.nlm.nih.gov/14695221/","model_system":"Five mouse tumour models with antitumour monoclonal antibody, in CR3-deficient, C3-deficient and granulocyte-depleted animals","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p14695221] Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. (2003). https://pubmed.ncbi.nlm.nih.gov/14695221/","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}